Liver receptor homolog-1: structures, related diseases, and drug discovery
Tong Wu1,2,3,
Zhi-fang Lu1,2,3,
Hao-nan Yu2,3,
Xi-shan Wu2,3,
Yang Liu1,
Yong Xu1,2,3
1 Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China
2 State Key Laboratory of Respiratory Disease, China-New Zealand Joint Laboratory of Biomedicine and Health, Guangdong Provincial Key Laboratory of Biocomputing, Center for Chemical Biology and Drug Discovery, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
3 Guangzhou Medical University, Guangzhou, China
Correspondence to: Yang Liu: y.liu@syphu.edu.cn, Yong Xu: xu_yong@gibh.ac.cn,
DOI: 10.1038/s41401-024-01276-x
Received: 6 February 2024
Accepted: 24 March 2024
Advance online: 17 April 2024
Abstract
Liver receptor homolog-1 (LRH-1), a member of the nuclear receptor superfamily, is a ligand-regulated transcription factor that plays crucial roles in metabolism, development, and immunity. Despite being classified as an ‘orphan’ receptor due to the ongoing debate surrounding its endogenous ligands, recent researches have demonstrated that LRH-1 can be modulated by various synthetic ligands. This highlights the potential of LRH-1 as an attractive drug target for the treatment of inflammation, metabolic disorders, and cancer. In this review, we provide an overview of the structural basis, functional activities, associated diseases, and advancements in therapeutic ligand research targeting LRH-1.
